skip to main content

H.R. 5354 (111th): GEDI Act

The text of the bill below is as of May 20, 2010 (Introduced).


I

111th CONGRESS

2d Session

H. R. 5354

IN THE HOUSE OF REPRESENTATIVES

May 20, 2010

(for himself, Mr. Burgess, Ms. DeGette, Mr. Castle, Mr. Gene Green of Texas, Mr. King of New York, Mrs. Capps, Mr. Gonzalez, Ms. Baldwin, Mr. Rangel, Mr. Higgins, Mrs. Maloney, Mr. Ackerman, Ms. Clarke, Ms. Lee of California, Mr. Serrano, and Mr. Doyle) introduced the following bill; which was referred to the Committee on Energy and Commerce

A BILL

To establish an Advisory Committee on Gestational Diabetes, to provide grants to better understand and reduce gestational diabetes, and for other purposes.

1.

Short title

This Act may be cited as the Gestational Diabetes Act of 2009 or the GEDI Act .

2.

Findings

The Congress finds the following:

(1)

The prevalence of gestational diabetes among pregnant women in the United States is increasing.

(2)

Gestational diabetes, which is similar to chronic forms of diabetes, normally appears at 24 to 28 weeks gestation and occurs in approximately 4 to 8 percent of pregnant women.

(3)

The associated risk factors for gestational diabetes include overweight, obesity, lack of physical activity, genetics, ethnicity, and age.

(4)

There is disagreement among physicians about how to treat gestational diabetes, as well as the effectiveness of current treatment regimens.

(5)

Gestational diabetes, which increases the risk of preeclampsia, also increases a pregnant woman’s risk for developing gestational diabetes in subsequent pregnancies.

(6)

Infants of women who develop gestational diabetes may have extreme increases in birth weight and the risks related to difficulties during the birthing process, and infants born to these women—

(A)

may subsequently have low blood sugar or jaundice during the newborn period;

(B)

are at increased risk for birth trauma; and

(C)

may be at increased risk of developing type 2 diabetes and obesity as an adolescent or adult.

(7)

Improved nutrition and increased physical activity before, during, and after pregnancy may significantly decrease the rates of gestational diabetes and its recurrence.

(8)

Obese pregnant women have a three-fold risk for the development of gestational diabetes as compared with normal weight women.

3.

Gestational diabetes

The Public Health Service Act (42 U.S.C. 201 et seq.) is amended by adding at the end the following:

XXXIII

Gestational Diabetes

3301.

Understanding and monitoring gestational diabetes during pregnancy

(a)

In General

The Secretary of Health and Human Services, acting through the Director of the Centers for Disease Control and Prevention, shall convene a Research Advisory Committee.

(b)

Membership

The members of the Research Advisory Committee—

(1)

shall include—

(A)

a representative from the Agency for Healthcare Research and Quality;

(B)

a representative from the Centers for Disease Control and Prevention;

(C)

a representative from the National Institutes of Health;

(D)

a representative from the Office of Minority Health;

(E)

a representative from the Indian Health Service;

(F)

a representative from the National Center for Health Statistics; and

(G)

representatives from other appropriate Federal agencies; and

(2)

may include representatives from other appropriate organizations.

(c)

Matters To Be Studied

The Director of the Centers for Disease Control and Prevention, in consultation with the Research Advisory Committee, shall develop a multisite, gestational diabetes research project within the diabetes program of the Centers for Disease Control and Prevention to expand and enhance surveillance data and public health research on gestational diabetes. The project shall address—

(1)

the procedures to establish accurate and efficient systems for the collection of gestational diabetes data within each State and commonwealth, territory, or possession of the United States;

(2)

the progress of collaborative activities with the National Vital Statistics System, the National Center for Health Statistics, and State health departments with respect to the standard birth certificate, in order to improve surveillance of gestational diabetes;

(3)

postnatal methods of tracking women who had gestational diabetes after delivery as well as targeted interventions proven to lower the incidence of type 2 diabetes in that population;

(4)

variations in the distribution of diagnosed and undiagnosed diabetes, and of impaired fasting glucose tolerance and impaired fasting glucose, within and among groups of women; and

(5)

factors and culturally sensitive interventions that influence risks and reduce the incidence of gestational diabetes during pregnancy and complications during childbirth, including cultural, behavioral, racial, ethnic, geographic, demographic, socioeconomic, and genetic factors.

(d)

Meetings

Not later than 1 year after the establishment of the gestational diabetes research project under subsection (c), and annually thereafter, the Research Advisory Committee shall meet to assess the progress of the project and to update the Secretary of Health and Human Services, if necessary.

(e)

Report

Not later than 2 years after the date of the enactment of this title, and annually thereafter, the Director of the Centers for Disease Control and Prevention shall generate a report on the prevalence and trends of gestational diabetes and disseminate the report to the Secretary of Health and Human Services and appropriate Federal and non-Federal agencies.

3302.

Demonstration grants to lower the rate of gestational diabetes during pregnancy

(a)

In General

The Secretary of Health and Human Services, acting through the Director of the Centers for Disease Control and Prevention, in consultation with the Research Advisory Committee established under section 3301, shall award grants, on a competitive basis, to eligible entities for demonstration projects that build capacity with key stakeholders, build new surveillance systems, and implement and evaluate evidence-based interventions to reduce the incidence of gestational diabetes and its recurrence and prevent type 2 diabetes after pregnancy. In making such grants, the Director give priority to projects focusing on—

(1)

helping women who have 1 or more risk factors for developing diabetes;

(2)

working with women who have had gestational diabetes during a previous pregnancy;

(3)

providing postnatal care for women who had gestational diabetes;

(4)

tracking cases where gestational diabetes led to the development of type 2 diabetes;

(5)

educating mothers about the increased risk of their child developing diabetes;

(6)

working to prevent or delay gestational diabetes and subsequent type 2 diabetes; and

(7)

achieving outcomes designed to assess efficacy and cost-effectiveness of interventions that can inform decisions on long-term sustainability, including third-party reimbursement.

(b)

Application

An eligible entity desiring to receive a grant under this section shall submit to the Director of the Centers for Disease Control and Prevention—

(1)

an application at such time, in such manner, and containing such information as the Director may require; and

(2)

a plan to—

(A)

lower the rate of gestational diabetes during pregnancy; or

(B)

develop methods of tracking women who had gestational diabetes and develop effective interventions to lower the incidence of the recurrence of gestational diabetes and the development of type 2 diabetes.

(c)

Uses of Funds

An entity receiving a grant under this section shall use the grant funds to carry out demonstration projects that implement evidence-based interventions to reduce the incidence of gestational diabetes and its recurrence, which may include—

(1)

expanding community-based health promotion education, activities, and incentives focused on the prevention of gestational diabetes and type 2 diabetes after pregnancy;

(2)

aiding State-based diabetes prevention and control programs to collect, analyze, disseminate, and report surveillance data on women with, and at risk for, gestational diabetes and its recurrence and prevention of type 2 diabetes after pregnancy;

(3)

building capacity with State-based partners to implement programs and interventions to reduce the occurrence of gestational diabetes based on surveillance data; and

(4)

training and encouraging health care providers—

(A)

to promote risk assessment, high-quality care, and self-management for gestational diabetes and its recurrence; and

(B)

to prevent type 2 diabetes after pregnancy and its complications in the practice settings of the health care providers.

(d)

Reports

(1)

CDC report

Not later than 4 years after the date of the enactment of this title, the Director of the Centers for Disease Control and Prevention shall prepare and submit a report to the Secretary of Health and Human Services concerning the results of the studies conducted through the grants awarded under this section.

(2)

Secretary report

Not later than 90 days after receiving the report described in paragraph (1), the Secretary shall prepare and submit a report to the Congress concerning the results and findings of the report.

(e)

Definition of Eligible Entity

In this section, the term eligible entity means a nonprofit organization (such as a nonprofit academic center or community health center) or a State or local health agency.

(f)

Authorization of Appropriations

There is authorized to be appropriated to carry out this section $5,000,000 for each fiscal year 2010 through 2014.

3303.

Research expansion of gestational diabetes during pregnancy

(a)

In General

The Director of the Centers for Disease Control and Prevention shall conduct and support public health research regarding gestational diabetes. Such research shall include—

(1)

developing and testing novel approaches for improving postpartum diabetes testing or screening and for preventing type 2 diabetes in women with a history of gestational diabetes; and

(2)

conducting public health research to further understanding of the epidemiologic, socioenvironmental, behavioral, translation, and biomedical factors and health systems that influence risk of gestational diabetes and progression to type 2 diabetes.

(b)

Authorization of Appropriations

There is authorized to be appropriated to carry out this section $5,000,000 for each fiscal year 2010 through 2014.

3304.

Screening for gestational diabetes

The Director of the Centers for Disease Control and Prevention shall encourage postpartum screenings after gestational diabetes within the State-based diabetes prevention and control programs assisted by the Centers for Disease Control and Prevention, for the purpose of reducing the incidence of gestational diabetes and its recurrence, progression to type 2 diabetes, and its related complications.

.